RESEARCH PROGRAMME OVERVIEW Attempts to Identify New Therapeutic Targets for Triple-Negative Breast Cancer
Targeted therapy is currently available for the majority of patients with newly diagnosed breast cancer.
Thus, patients with estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive disease
receive hormone therapy, while patients with HER2-postive disease may be treated with trastuzumab
(Herceptin). For patients lacking ER/PR and HER2 overexpression however, targeted therapy is currently
unavailable. Consequently, the only systemic therapy available for this subgroup of patients which have
been dubbed triple-negative, is chemotherapy. Currently, there is intense interest worldwide in developing
new targeted therapies for patients with triple-negative breast cancer.
Workpackage 1 of the MTCI projects aims to identify such new targets with a focus on specific ADAMs
and c-Met. ADAMs are proteases that activate the precursor forms of growth factors and cytokines. They
thus play a critical role in cell signalling, acting upstream of receptor binding and activation. Two
ADAMs have a particular relevance for malignancy, ie, ADAM10 and ADAM17. These 2 ADAMs
release all the growth factors that activate the EGFR/HER family of receptors. Inhibiting these ADAMs
might thus be expected to block EGFR/HER signalling and thus prevent cell growth and migration.
MET is a tyrosine kinase receptor that, upon binding of its natural ligand, HGF, is phosphorylated and
subsequently activates different signalling pathways involved in proliferation, motility, migration and
invasion. MET has been found to be aberrantly activated in human cancer via mutation, amplification or
protein overexpression. Recent findings suggest that c-Met in involved in the formation and progression of
basal-type breast cancer. (Most basal-type breast cancers are also triple-negative). c-Met might thus be
expected to be a good therapeutic target for treating triple-negative breast cancer.
Micro (mi)RNAs are small non-protein coding RNA (approximately 22 nucleotides) molecules that
regulate gene expression; generally at the post-transcriptional level. Such RNAs may contribute to cancer
formation and progression by regulating the expression of c-oncogenes and tumor suppressor genes or by
acting as oncogenes or tumor suppressor genes. Recent evidence suggests that specific miRNAs, as well
as mRNAs, may have a role as extracellular biomarkers. In this investigation, miRNAs and mRNAs are
being investigated as potential biomarkers for both predicting response to the new therapies as well as
monitoring the effectiveness of response.
1. To evaluate ADAM10 and ADAM17 as potential therapeutic targets for the treatment of triple-
2. To evaluate c-Met as a potential therapeutic targets for the treatment of triple-negative breast
3. To evaluate miRNAs and mRNAs as biomarkers for predicting and monitoring response to these
RESEARCH TEAM ADAMs Group
Dr Patricia McGowan, Post-doctoral Fellow
Dr Aisling Pierce*, Post-Doctoral Fellow
c-Met Group miRNA/mRNA Group
*These investigators are not directly funded from the MTCI grant
RECENT PUBLICATIONS / KEY OUTPUTS
1. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in
cancer patients. Cancer Treat Rev. 2010 Aug 2. [Epub ahead of print]
2. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of
IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann
Oncol. 2010 Jul 20. [Epub ahead of print]
3. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J,
O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance
to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502. Epub 2010 May 25.
4. Walsh S, Tryfonopoulos D, Quinn C, Flanagan L, Pierce A, McDermott E, Evoy D, O’Donovan N,
Crown J, Duffy MJ. c-Src: A Potential Target for the Treatment of Triple-Negative Breast Cancer.
J Clin Oncol 2010;28:7s, (suppl; abst 10617)
5. Friel AM, Corcoran C, Crown J, O'Driscoll L. Relevance of circulating tumor cells, extracellular
nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat. 2010 Jun 15. [Epub ahead
6. Germano S, Rani S, Kennedy S, Crown J, Clynes M, O’Driscoll L (2010). Melanoma-associated
antigen family protein-D4: clinical significance and funcational relevance in breast cancer. Breast
Cancer Res. 12; S10-11 (suppl 1; abstract 32)
7. Friel AM, Crown J, O’Driscoll L (2010). Analysis of gene expression as relevant to cancer cells
and circulating tumour cells In: Gene Expression Profiling; Methods in Molecular Biology (in
Medico Neurologo UO Medicina I Presidio Ospedaliero di Magenta Laurea in Medicina e Chirurgia il 20.02.1987 con 110/110 e Lode Specialità in Neurologia nel 1991 con 50/50; Neurofisiopatologia nel 2002 con 50/50 e Lode Medico Neurologo UO Medicina I Presidio Ospedaliero di Magenta Medico frequentatore presso l'Istituto Neurologico "Carlo Besta" dal 19/02/1988 al 31/12/1990 e Borsist
— MESSAGE DISCLAIMER — These messages are offered for your personal edification and enrichment. There is no legal copyright on this material. I have used many sources, and I have always attempted to cite any exact quotations. Any failure to cite a quote is simply an oversight on my part. If you are a preacher or teacher, I enco